Controlled release of rhBMP-2 loaded poly(dl-lactic-co-glycolic acid)/calcium phosphate cement composites in vivo.

The release kinetics of recombinant human bone morphogenetic protein-2 (rhBMP-2) loaded poly(dl-lactic-co-glycolic acid)/calcium phosphate cement (PLGA/Ca-P cement) composites were studied in vivo. RhBMP-2 was radiolabeled with (131)I and entrapped within PLGA microparticles or adsorbed onto the microparticle surface. PLGA microparticles were prepared of high molecular weight (HMW) PLGA (weight average molecular weight [M(w)] 49,100+/-1700) or low molecular weight (LMW) PLGA (M(w) 5,900+/-300) and used for preparation of 30:70 wt.% PLGA/Ca-P cement composite discs. Release of 131I-rhBMP-2 loaded composites was assessed by scintigraphic imaging according to a 2(2) two-level full factorial design in the rat ectopic model during four weeks. In vivo release kinetics varied among formulations. All formulations showed slow release without initial burst, and displayed a linear release from 3 to 28 days. Release of LMW entrapped rhBMP-2 composites (1.7+/-0.3%/day) was significantly faster than release from other formulations (p<0.01). After 28 days, retention within the composites was 65+/-5%, 75+/-4%, 50+/-4% and 70+/-6% of the initial rhBMP-2 for HMW entrapped, HMW adsorbed, LMW entrapped and LMW adsorbed rhBMP-2 composites, respectively. Release from the composite was probably slowed down by an interaction of rhBMP-2 and Ca-P cement after rhBMP-2 release from PLGA microparticles. We conclude that PLGA/Ca-P cement composites can be considered as sustained slow release vehicles and that the release and retention of rhBMP-2 can be modified according to the desired profile to a limited extent.

[1]  J. Jansen,et al.  Biocompatibility and degradation of poly(DL-lactic-co-glycolic acid)/calcium phosphate cement composites. , 2005, Journal of biomedical materials research. Part A.

[2]  G. Sándor,et al.  Closure of Critical Sized Defects With Allogenic and Alloplastic Bone Substitutes , 2002, The Journal of craniofacial surgery.

[3]  J. Wozney,et al.  Implantation of recombinant human bone morphogenetic proteins with biomaterial carriers: A correlation between protein pharmacokinetics and osteoinduction in the rat ectopic model. , 2000, Journal of biomedical materials research.

[4]  L. Chow Calcium phosphate cements. , 2001, Monographs in oral science.

[5]  A. Mikos,et al.  Inhibition of smooth muscle cell growth in vitro by an antisense oligodeoxynucleotide released from poly(DL-lactic-co-glycolic acid) microparticles. , 1997, Journal of biomedical materials research.

[6]  V. Paralkar,et al.  Osteogenin and recombinant bone morphogenetic protein 2B are chemotactic for human monocytes and stimulate transforming growth factor beta 1 mRNA expression. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[7]  R. Z. LeGeros,et al.  1. Introduction — Scope , 1991 .

[8]  R Z LeGeros,et al.  Calcium phosphates in oral biology and medicine. , 1991, Monographs in oral science.

[9]  H. Seeherman,et al.  Retention of 125I‐labeled recombinant human bone morphogenetic protein‐2 by biphasic calcium phosphate or a composite sponge in a rabbit posterolateral spine arthrodesis model , 2002, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[10]  T. Bauer,et al.  Use of injectable calcium phosphate cement for fracture fixation: a review. , 2002, Clinical orthopaedics and related research.

[11]  J. Jansen,et al.  Trabecular bone response to injectable calcium phosphate (Ca-P) cement. , 2002, Journal of biomedical materials research.

[12]  A. Mikos,et al.  Controlled release of transforming growth factor β1 from biodegradable polymer microparticles , 2000 .

[13]  Henry C. Vasconez,et al.  Enhancement of Bone Growth by Sustained Delivery of Recombinant Human Bone Morphogenetic Protein-2 in a Polymeric Matrix , 2001, Pharmaceutical Research.

[14]  M. Shive,et al.  Biodegradation and biocompatibility of PLA and PLGA microspheres , 1997 .

[15]  A. Reddi,et al.  Initiation and promotion of bone differentiation by bone morphogenetic proteins , 1993, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[16]  J. Benoit,et al.  NGF release from poly(D,L-lactide-co-glycolide) microspheres. Effect of some formulation parameters on encapsulated NGF stability. , 1998, Journal of controlled release : official journal of the Controlled Release Society.

[17]  P. Fraker,et al.  Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril. , 1978, Biochemical and biophysical research communications.

[18]  A. Ladd,et al.  Use of bone-graft substitutes in distal radius fractures. , 1999, The Journal of the American Academy of Orthopaedic Surgeons.

[19]  J. Wozney,et al.  Characterization of rhBMP-2 pharmacokinetics implanted with biomaterial carriers in the rat ectopic model. , 1999, Journal of biomedical materials research.

[20]  J. Wozney,et al.  Delivery Systems for BMPs: Factors Contributing to Protein Retention at an Application Site , 2001, The Journal of bone and joint surgery. American volume.

[21]  M J Yaszemski,et al.  Effects of transforming growth factor beta1 released from biodegradable polymer microparticles on marrow stromal osteoblasts cultured on poly(propylene fumarate) substrates. , 2000, Journal of biomedical materials research.

[22]  J. Jansen,et al.  A new method to produce macropores in calcium phosphate cements. , 2002, Biomaterials.

[23]  C. Friedman,et al.  BoneSource hydroxyapatite cement: a novel biomaterial for craniofacial skeletal tissue engineering and reconstruction. , 1998, Journal of biomedical materials research.

[24]  J A Schrier,et al.  Recombinant human bone morphogenetic protein-2 binding and incorporation in PLGA microsphere delivery systems. , 1999, Pharmaceutical development and technology.

[25]  Antonios G Mikos,et al.  rhBMP-2 Release from Injectable Poly(DL-Lactic-co-glycolic Acid)/Calcium-Phosphate Cement Composites , 2003, The Journal of bone and joint surgery. American volume.

[26]  B L Currier,et al.  Biological activity of rhBMP-2 released from PLGA microspheres. , 2000, Journal of biomechanical engineering.

[27]  H. Ozawa,et al.  Long-term evaluation of recombinant human bone morphogenetic protein-2 induced bone formation with a biologic and synthetic delivery system. , 1996, The British journal of oral & maxillofacial surgery.

[28]  D. Puleo,et al.  In vitro cellular responses to bioerodible particles loaded with recombinant human bone morphogenetic protein-2. , 1998, Journal of biomedical materials research.